Clover Health Investments Corp (CLOV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Clover Health Investments Corp (CLOV) Financials: Revenue, Profit and Cash Flow
Clover Health Investments reported revenue of $1.92B for the fiscal year ended Dec 31, 2025, up 40.4% from the year before. That year, net income was -$85.55M with a net margin of -4.4%, operating cash flow was -$66.93M and free cash flow was -$68.98M. The quarter ended Sep 30, 2026 had revenue of $759.30M and net income of $6.43M.
Revenue and Margins
The operating margin was -4.4% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $281.02M, a compound annual rate of 31.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.92B | +40.4% | 18.5% | -4.4% | -4.4% |
| Dec 2024 | $1.37B | +9.1% | 26.6% | -3.3% | -3.1% |
| Dec 2023 | $1.26B | +13.6% | 20.4% | -16.4% | -17.0% |
| Dec 2022 | $1.11B | -24.7% | 9.4% | -25.9% | -30.7% |
| Dec 2021 | $1.47B | +101.0% | -5.4% | -43.4% | -40.0% |
| Dec 2020 | $730.65M | +156.7% | 11.3% | -12.7% | -18.7% |
| Dec 2019 | $284.68M | +1.3% | 4.4% | -64.4% | -127.8% |
| Dec 2018 | $281.02M | N/A | 100.0% | -66.1% | -71.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $1.26B | $1.11B | $1.47B | $730.65M | $284.68M | $281.02M |
| Cost of revenue | $1.57B | $1.01B | $1.00B | $993.07M | $1.55B | $590.08M | $449.70M | N/A |
| Gross profit | $355.88M | $364.80M | $255.95M | $103.48M | -$79.18M | $82.81M | $12.56M | $281.02M |
| Operating income | -$85.53M | -$45.75M | -$205.33M | -$286.66M | -$636.99M | -$92.71M | -$183.20M | -$185.80M |
| Net income | -$85.55M | -$43.01M | -$213.36M | -$339.57M | -$587.76M | -$136.39M | -$363.74M | -$201.93M |
| EBITDA | N/A | N/A | N/A | -$255.34M | N/A | $45.74M | N/A | -$16.13M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $759.30M | $743.17M | $749.19M | $487.71M | $496.65M | $477.62M | $462.33M | $336.50M | $330.99M | $356.26M | $346.92M | $307.66M |
| Gross profit | N/A | N/A | $159.54M | $74.21M | $73.18M | $99.63M | $108.89M | $93.92M | $81.21M | $107.91M | $81.76M | $62.27M |
| Operating income | N/A | N/A | $27.33M | -$49.32M | -$24.38M | -$10.56M | -$1.27M | -$21.45M | -$8.79M | $7.19M | -$22.70M | -$65.66M |
| Net income | $6.43M | $28.00M | $27.33M | -$49.32M | -$24.38M | -$10.58M | -$1.27M | -$22.09M | -$9.15M | $7.41M | -$19.17M | -$70.47M |
Balance Sheet
As of Dec 2025, cash and equivalents of $78.30M were 14.5% of total assets of $541.01M, against total liabilities of $232.31M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $541.01M | $580.74M | $570.67M | $808.62M | $950.80M | $267.25M | $100.35K | $210.60M |
| Current assets | $307.86M | $343.12M | $427.97M | $625.00M | $752.55M | $189.78M | $67.60M | $75.40M |
| Cash and equivalents | $78.30M | $194.54M | $116.41M | $103.79M | $299.97M | $92.35M | $0 | $75.40M |
| Total liabilities | $232.31M | $239.60M | $284.28M | $451.73M | $411.49M | $432.70M | $117.98K | $265.42M |
| Short-term debt | N/A | N/A | $1.67M | $222.03M | $74.66M | $20.80M | $0 | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | $19.94M | $106.41M | N/A | N/A |
| Shareholder equity | $308.70M | $341.09M | $286.39M | $356.89M | $535.41M | -$617.10M | -$17.63K | -$54.83M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $753.68M | $720.33M | $697.73M | $541.01M | $559.66M | $574.99M | $583.72M | $580.74M | $653.01M | $674.21M | $671.77M | $570.67M |
| Total liabilities | $362.81M | $344.07M | $358.30M | $232.31M | $218.73M | $230.81M | $247.64M | $239.60M | $310.85M | $349.32M | $379.30M | $284.28M |
| Cash and equivalents | $268.07M | $198.84M | $173.26M | $78.30M | $190.06M | $188.65M | $155.44M | $194.54M | $287.96M | $254.77M | $208.25M | $116.41M |
| Shareholder equity | $390.87M | $376.26M | $339.43M | $308.70M | $340.93M | $344.18M | $336.07M | $341.14M | $342.17M | $324.89M | $292.47M | $286.39M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.93M | $34.84M | -$144.66M | -$203.93M | -$282.33M | -$118.50M | -$159.88M | -$153.28M |
| Capital expenditures | $2.04M | $1.56M | $584.00K | $4.47M | $723.00K | $693.00K | $23.00K | $1.48M |
| Free cash flow | -$68.98M | $33.29M | -$145.25M | -$208.39M | -$283.05M | -$119.19M | -$159.90M | -$154.76M |
| Dividends paid | N/A | N/A | N/A | N/A | $305.00K | $957.00K | N/A | N/A |
| Share repurchases | $18.30M | $1.77M | $0 | $6.36M | $232.00K | $957.00K | $0 | N/A |
| Investing cash flow | $4.08M | $565.00K | $140.01M | $95.13M | -$435.45M | $137.40M | -$181.91M | $97.53M |
| Financing cash flow | -$53.38M | -$17.36M | -$5.07M | -$4.96M | $925.39M | $5.84M | $333.98M | $74.59M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $70.38M | $25.19M | $107.89M | -$68.15M | $12.10M | $5.41M | -$16.29M | -$85.83M | $49.99M | $44.76M | $25.93M | -$258.09M |
| Capital expenditures | $898.00K | $682.00K | $854.00K | $597.00K | $692.00K | $569.00K | $185.00K | $315.00K | $399.00K | $397.00K | $445.00K | $264.00K |
| Free cash flow | $69.48M | $24.51M | $107.04M | -$68.75M | $11.41M | $4.84M | -$16.48M | -$86.15M | $49.59M | $44.36M | $25.49M | -$258.35M |
Frequently Asked Questions About CLOV
What is Clover Health Investments' annual revenue?
Clover Health Investments reported revenue of $1.92B for the fiscal year ended Dec 31, 2025.
How fast is Clover Health Investments' revenue growing?
Revenue was up 40.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.3%.
Is Clover Health Investments profitable?
No. Clover Health Investments reported net income of -$85.55M for the fiscal year ended Dec 31, 2025, with a net margin of -4.4%.
How much free cash flow does CLOV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$66.93M minus capital expenditures of $2.04M produced free cash flow of -$68.98M.
How much debt does Clover Health Investments have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $78.30M.
CLOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors